FORTRESS BIOTECH, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.87 USD | +1.67% |
|
+1.73% | +33.70% |
| 05-15 | Fortress Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 05-15 | Earnings Flash (FBIO) FORTRESS BIOTECH Posts Q1 Revenue $13M | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 181.9 | 300.5 | 249.1 | 71.14 | 54.57 | 36.65 | - | - |
| Enterprise Value (EV) 1 | 181.9 | 300.5 | 249.1 | 71.14 | 54.57 | 36.65 | 36.65 | 36.65 |
| P/E ratio | -3.52 x | -4.88 x | -3.16 x | -0.68 x | -0.36 x | -0.39 x | -0.57 x | -0.64 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 4.97 x | 6.59 x | 3.62 x | 0.94 x | 0.65 x | 0.5 x | 0.29 x | 0.22 x |
| EV / Revenue | 4.97 x | 6.59 x | 3.62 x | 0.94 x | 0.65 x | 0.5 x | 0.29 x | 0.22 x |
| EV / EBITDA | -1.67 x | -3.27 x | -1.32 x | - | - | -0.24 x | -0.3 x | -0.32 x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 4,719 | 6,320 | 6,642 | 7,241 | 18,131 | 19,916 | - | - |
| Reference price 2 | 38.55 | 47.55 | 37.50 | 9.825 | 3.010 | 1.840 | 1.840 | 1.840 |
| Announcement Date | 3/16/20 | 3/31/21 | 3/28/22 | 3/30/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 36.63 | 45.6 | 68.79 | 75.74 | 84.51 | 73.92 | 126 | 168.1 |
| EBITDA 1 | -108.9 | -91.99 | -188.5 | - | - | -154.6 | -121.4 | -115.6 |
| EBIT 1 | -110.8 | -94.27 | -188.5 | -203.6 | -142.3 | -135.2 | -105.9 | -87.47 |
| Operating Margin | -302.54% | -206.74% | -274.08% | -268.76% | -168.43% | -182.84% | -84.09% | -52.02% |
| Earnings before Tax (EBT) 1 | -101.7 | -102.8 | -164.4 | -213.5 | -153.6 | -137.8 | -114.6 | -95.55 |
| Net income 1 | -39.96 | -46.53 | -64.7 | -86.58 | -68.67 | -89.45 | -75.78 | -74.52 |
| Net margin | -109.09% | -102.03% | -94.06% | -114.3% | -81.25% | -121.02% | -60.17% | -44.33% |
| EPS 2 | -10.95 | -9.750 | -11.85 | -14.55 | -8.470 | -4.710 | -3.207 | -2.855 |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/16/20 | 3/31/21 | 3/28/22 | 3/30/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 18.28 | 23.92 | 18.89 | 16.53 | 16.4 | 12.43 | 17.39 | 34.54 | 20.59 | 13.03 | 14.77 | 24.07 | 22.05 |
| EBITDA 1 | -62 | -47.27 | -50.93 | -50.73 | - | - | - | - | - | -35.38 | -36.6 | -44.9 | -36.5 |
| EBIT 1 | -62 | -47.27 | -50.93 | -50.73 | -54.63 | -58.87 | -50.1 | 17.24 | -142.4 | -36.57 | -34.23 | -22.44 | -32.19 |
| Operating Margin | -339.25% | -197.58% | -269.65% | -306.96% | -333.05% | -473.63% | -288.19% | 49.93% | -691.5% | -280.63% | -231.68% | -93.24% | -146.03% |
| Earnings before Tax (EBT) 1 | -68.04 | -49.48 | -53.93 | -53.06 | -57 | -55.14 | -59.3 | 16.88 | -152 | -39.02 | -37.01 | -32.28 | -36.59 |
| Net income 1 | -31.56 | -15.76 | -21.36 | -22.51 | -26.95 | -21.54 | -24.78 | 16.79 | -66.96 | -17.73 | -23.37 | -24.57 | -23.8 |
| Net margin | -172.71% | -65.87% | -113.08% | -136.2% | -164.28% | -173.28% | -142.51% | 48.61% | -325.22% | -136.08% | -158.23% | -102.07% | -107.94% |
| EPS 2 | -5.700 | -2.700 | -3.600 | -3.750 | -4.500 | -3.150 | -3.360 | 0.8000 | -8.380 | -1.030 | -1.223 | -1.230 | -1.183 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/28/22 | 5/12/22 | 8/11/22 | 11/14/22 | 3/30/23 | 5/15/23 | 8/14/23 | 11/7/23 | 3/28/24 | 5/15/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | -21.40 | -30.30 | - | - | - | - |
| Capex | 2.35 | 5.96 | 4.57 | 2.72 | - | - | - | - |
| Capex / Sales | 6.4% | 13.08% | 6.64% | 3.58% | - | - | - | - |
| Announcement Date | 3/16/20 | 3/31/21 | 3/28/22 | 3/30/23 | 3/28/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.84
USD
Average target price
10.75
USD
Spread / Average Target
+484.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -2.29% | 89.87B | |
| -3.95% | 37.57B | |
| -13.07% | 32.75B | |
| +63.05% | 26.47B | |
| -22.14% | 14.25B | |
| -7.96% | 12.99B | |
| -9.33% | 11.93B | |
| -46.33% | 10.84B | |
| +5.77% | 9.11B |
- Stock Market
- Equities
- FBIO Stock
- FBIOP Stock
- Financials Fortress Biotech, Inc.
